title: Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.
abstract: Phosphoinositide 3'-kinase (PI3K) is a key node in the B-cell receptor pathway, which plays a crucial role in the trafficking, survival, and proliferation of chronic lymphocytic leukemia (CLL) cells. This article reviews the biology of PI3K, focusing on its relationship to the CLL microenvironment, and discusses the biological rationale for PI3K inhibition in CLL. Preliminary safety and efficacy data from early phase clinical trials is also discussed. Potential biomarkers for clinical response to PI3K inhibitors such as ZAP-70, IGHV status, and CCL3 are examined. Where PI3K inhibition may fit in the evolving landscape of CLL therapy is also explored.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, CLL Center, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Davids
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Brown
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000201:enzymology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011379:Prognosis; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases
references.citation: Cancer. 2010 May 1;116(9):2201-7
references.pmid: 20166206
references.citation: Blood. 2011 Apr 21;117(16):4323-7
references.pmid: 21378270
references.citation: Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
references.pmid: 20615965
references.citation: Blood. 2004 Jun 15;103(12):4389-95
references.pmid: 14962897
references.citation: Blood. 2009 Mar 26;113(13):3050-8
references.pmid: 19074730
references.citation: Annu Rev Immunol. 1992;10:97-121
references.pmid: 1591006
references.citation: Immunol Rev. 2009 Nov;232(1):300-18
references.pmid: 19909372
references.citation: Leukemia. 2011 May;25(5):828-37
references.pmid: 21372840
references.citation: Blood. 2008 Aug 1;112(3):782-92
references.pmid: 18487510
references.citation: Blood. 2009 Oct 15;114(16):3367-75
references.pmid: 19636060
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4330-5
references.pmid: 9113989
references.citation: Clin Cancer Res. 2012 Jul 15;18(14):3791-802
references.pmid: 22623730
references.citation: Blood. 2011 Sep 29;118(13):3603-12
references.pmid: 21803855
references.citation: J Exp Med. 1993 Jun 1;177(6):1821-6
references.pmid: 7684437
references.citation: N Engl J Med. 2005 Feb 24;352(8):804-15
references.pmid: 15728813
references.citation: Blood. 2011 Jan 13;117(2):563-74
references.pmid: 20940416
references.citation: Cell Death Differ. 2005 Mar;12(3):233-42
references.pmid: 15665818
references.citation: Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62
references.pmid: 17052169
references.citation: Leukemia. 1997 Feb;11(2):258-65
references.pmid: 9009090
references.citation: Blood. 2006 May 1;107(9):3584-92
references.pmid: 16332969
references.citation: N Engl J Med. 2011 Dec 29;365(26):2497-506
references.pmid: 22150006
references.citation: Biochem J. 2012 Mar 15;442(3):465-81
references.pmid: 22364281
references.citation: Cancer Cell. 2005 Oct;8(4):287-97
references.pmid: 16226704
references.citation: Trends Biochem Sci. 2005 Apr;30(4):194-204
references.pmid: 15817396
references.citation: J Biol Chem. 1997 Aug 1;272(31):19236-41
references.pmid: 9235916
references.citation: Nat Immunol. 2003 Apr;4(4):313-9
references.pmid: 12660731
references.citation: Leukemia. 2005 Apr;19(4):513-23
references.pmid: 15703780
references.citation: Cancer Cell. 2003 Oct;4(4):257-62
references.pmid: 14585353
references.citation: Blood. 2003 Jun 15;101(12):4944-51
references.pmid: 12595313
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Nat Rev Immunol. 2006 Apr;6(4):283-94
references.pmid: 16557260
references.citation: J Clin Oncol. 2012 Aug 10;30(23):2820-2
references.pmid: 22778323
references.citation: Expert Rev Mol Med. 2008 Feb 04;10:e4
references.pmid: 18241520
references.citation: Blood. 2011 Jan 13;117(2):591-4
references.pmid: 20959606
references.citation: Nature. 2011 Jun 05;475(7354):101-5
references.pmid: 21642962
references.citation: Blood. 2010 Sep 23;116(12):2078-88
references.pmid: 20522708
references.citation: Blood. 2009 May 28;113(22):5549-57
references.pmid: 19318683
references.citation: J Immunol. 2008 Feb 15;180(4):2081-8
references.pmid: 18250413
references.citation: Dtsch Med Wochenschr. 2008 Jun;133(25-26):1400-4
references.pmid: 18553270
references.citation: Blood. 1999 Sep 15;94(6):1848-54
references.pmid: 10477713
references.citation: Blood. 2012 Oct 25;120(17):3501-9
references.pmid: 22955911
references.citation: Blood. 2010 Apr 1;115(13):2578-85
references.pmid: 19965662